Showing results (811-820 of 821) with videos related to

Sort By:
Pageof 83
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.
Cancer Discovery|April 9, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET RearrangementsSeshiru Nakazawa, Federica Pecci, Igor Odintsov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAE Felip, B C Cho, V Gutiérrez, et al.
Genome Biology|March 30, 2021
Comprehensive identification of somatic nucleotide variants in human brain tissueYifan Wang, Taejeong Bae, Jeremy Thorpe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 9, 2024
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian studyB M Piraccini, F Pampaloni, S Cedirian, et al.
Italian Journal of Dermatology and Venereology|May 29, 2024
Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patientsBianca Maria Piraccini, Luca Rapparini, Federico Quadrelli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2025
Effectiveness and safety of baricitinib in severe alopecia areata: 48-week resultsBianca Maria Piraccini, Stephano Cedirian, Francesca Pampaloni, et al.
American Journal of Clinical Dermatology|March 19, 2026
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World StudyMichela Starace, Luca Rapparini, Francesca Pampaloni, et al.
The British Journal of Dermatology|September 30, 2018
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patientsJ J Scarisbrick, P Quaglino, H M Prince, et al.
Trials|July 3, 2024
Comparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial)Giovanni Vento, Angela Paladini, C Aurilia, et al.
Pageof 83